GelSana Therapeutics, Inc.

GelSana Therapeutics is a biomaterials company that specializes in developing advanced wound care solutions powered by proprietary zwitterionic polymer technology. Founded in 2020, the company engineers hydrogel-based products designed to address excess sustained inflammation, a primary barrier to natural healing in chronic wounds, surgical incisions, and burns. Their signature product, CleraFlex, is a stretchable, moldable wound dressing that creates a protective barrier to balance moisture, repel bacteria, and support the body’s natural healing cascade without triggering adverse immune responses. The dressing is designed to be highly adaptable, conforming to irregular wound geometries and providing a versatile solution for clinical application.

These technologies are intended to improve patient outcomes by accelerating healing, reducing the risk of complications such as infection and amputation, and simplifying the care process for healthcare providers. By focusing on the biological mechanisms of difficult-to-heal wounds, GelSana aims to replace conventional dressings with materials that actively support healing. The company, headquartered in Aurora, Colorado, works with clinical advisors and partners to translate academic research into viable clinical products, supported by funding from sources including the Department of Defense SBIR program and various venture capital initiatives.